The Comparision of Hepatitis C Virus (HCV) Core Antigen and HCV RNA Levels for Diagnosis of HCV Infection in Haemodialysis Patients

Kizilates, Filiz; Cekin, Yesim; Sari, Funda; Sarikaya, Metin; Seyman, Derya; Oztoprak, Nefise; Cetinkaya, Ramazan
August 2013
HealthMed;2013, Vol. 7 Issue 8, p2395
Academic Journal
The diagnosis and monitoring of HCV infection are commonly based on anti-HCV assays. But anti-HCV assays indicate only the exposure of virus therefore confirmation with nucleic acid amplification assays is supposed. Architect HCV Ag assay is recently developed for detecting HCV nucleocapsid antigen (HCV Ag) in serum and plasma. We aimed to evaluate the usefulness of HCV Ag test for the diagnosis of HCV infection and to determine the correlation between HCV Ag test and quantitative HCV RNA assay in haemodialysis (HD) patients. Three hundred fifty-six HD patients were included in the study. Anti-HCV assay, HCV Ag test and HCV RNA were studied in all sera. A significant relationship was determined between HCV RNA positivity and HCV Ag positivity by Chi-square test (p<0.001 ). The HCV Ag levels were correlated with HCV RNA levels (Spearman test coefficient 0.867, p<0.001). The diagnostic sensitivity and specificity of HCV core Ag assay compared to the HCV RNA assay were 96.15% and 100%, respectively. Architect HCV Ag assay is high sensitive and specific to diagnose of HCV infection. Therefore, HCV Ag assay can be used alternative to HCV RNA assays, especially in immunocompromised individuals as HD patients.


Related Articles

  • Good outcomes of liver transplantation for hepatitis C at a low volume centre. Su Yin Lau; Woodman, Richard J.; Silva, Mauricio F.; Muller, Kate; Libby, John; Chen, John W.; Padbury, Robert; Wigg, Alan J. // Annals of Hepatology: Official Journal of the Mexican Associatio;Mar/Apr2016, Vol. 15 Issue 2, p207 

    Background and aims. Concerns exist about outcomes of liver transplantation (LT) from low volume centres, especially for hepatitis C (HCV) patients. The aim of the study was to assess patient outcomes as well as their predictors post LT for HCV in a small volume Australian unit (< 25 LTs/year),...

  • Utility of routine real time quantitative PCR monitoring of HCV infection in haemodialysis patients. Datta, S.; Goel, N.; Wattal, C. // Indian Journal of Medical Microbiology;2015 Supplement 1, Vol. 33, pS106 

    Background: Hepatitis C virus (HCV) infection causes significant morbidity and mortality in patients of end stage renal disease (ESRD) on haemodialysis (HD). Stringent screening methods can help in its early diagnosis. Objective: The study addresses the utility of real-time quantitative...

  • Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. Trinks, J; Hulaniuk, M L; Caputo, M; Pratx, L Burgos; Ré, V; Fortuny, L; Pontoriero, A; Frías, A; Torres, O; Nuñez, F; Gadano, A; Corach, D; Flichman, D // Pharmacogenomics Journal;Dec2014, Vol. 14 Issue 6, p549 

    The prevalence of genetic polymorphisms identified as predictors of therapeutic-induced hepatitis C virus (HCV) clearance differs among ethnic groups. However, there is a paucity of information about their prevalence in South American populations, whose genetic background is highly admixed....

  • Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Zoulim, Fabien; Liang, T. Jake; Gerbes, Alexander L.; Aghemo, Alessio; Deuffic-Burban, Sylvie; Dusheiko, Geoffrey; Fried, Michael W.; Pol, Stanislas; Rockstroh, Jürgen Kurt; Terrault, Norah A.; Wiktor, Stefan // Gut;Nov2015, Vol. 64 Issue 11, p1824 

    Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past...

  • Synonymous Co-Variation across the E1/E2 Gene Junction of Hepatitis C Virus Defines Virion Fitness. Palmer, Brendan A.; Fanning, Liam J. // PLoS ONE;11/23/2016, Vol. 11 Issue 11, p1 

    Hepatitis C virus is a positive-sense single-stranded RNA virus. The gene junction partitioning the viral glycoproteins E1 and E2 displays concurrent sequence evolution with the 3′-end of E1 highly conserved and the 5′-end of E2 highly heterogeneous. This gene junction is also...

  • Treating Hepatitis C in Patients with Renal Failure. Lens, Sabela; Rodriguez-Tajes, Sergio; Llovet, Laura-Patricia; Maduell, Francisco; Londoño, Maria-Carlota // Digestive Diseases;May2017, Vol. 35 Issue 4, p339 

    Background: There is a strong relationship between hepatitis C virus (HCV) infection and the kidney. Approximately 10-16% of the patients with HCV infection develop renal disease, and the prevalence of HCV infection in patients with renal dysfunction is higher than that of the general population...

  • The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus. Eley, Timothy; Sevinsky, Heather; Huang, Shu-Pang; He, Bing; Zhu, Kurt; Kandoussi, Hamza; Gardiner, David; Grasela, Dennis; Bertz, Richard; Bifano, Marc // Clinical Drug Investigation;Sep2014, Vol. 34 Issue 9, p661 

    Background and Objectives: The combination of direct-acting antiviral agents in patients with chronic hepatitis C virus (HCV) infection has demonstrated clinical benefit; however, evaluation of potential drug-drug interactions is required prior to therapy. Methods: An open-label study assessed...

  • Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients. Sun, Hong; Buzon, Maria J.; Shaw, Amy; Berg, Randi Karteebahn; Yu, Xu G.; Ferrando-Martinez, Sara; Leal, Manuel; Ruiz-Mateos, Ezequiel; Lichterfeld, Mathias // Journal of Infectious Diseases;May2014, Vol. 209 Issue 9, p1315 

    Combined treatment with interferon alpha (IFN-α) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with...

  • An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C. O'Brien, Thomas R.; Everhart, James E.; Morgan, Timothy R.; Lok, Anna S.; Chung, Raymond T.; Shao, Yongwu; Shiffman, Mitchell L.; Dotrang, Myhanh; Sninsky, John J.; Bonkovsky, Herbert L.; Pfeiffer, Ruth M. // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Background: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after pegylated-interferon/ribavirin treatment for chronic hepatitis C (CHC). Using data from the HALT-C Trial, we developed a model to predict a patient's probability of SVR based...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics